Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090586 | 0.84 | MAOB (0.62) | PTGS2MAOBTMEM97 | |
| SCHEMBL7085155 | 0.82 | PTGS2 (0.48) | PTGS2 | |
| SCHEMBL7089387 | 0.82 | PTGS2 (0.48) | PTGS2MAOB | |
| SCHEMBL6725743 | 0.82 | PTGS2 (0.76) | PTGS2ABCB1 | |
| SCHEMBL7085561 | 0.76 | PTGS2 (0.56) | PTGS2 | |
| SCHEMBL25490919 | 0.75 | PLAU (0.58) | PTGS2MAOBABCB1 | |
| SCHEMBL8652041 | 0.75 | PTGS2 (0.62) | PTGS2 | |
| SCHEMBL17295958 | 0.74 | ABCB1 (0.52) | MAOBABCB1ABCC1HTR7 | |
| SCHEMBL7084451 | 0.73 | FFAR1 (0.44) | PTGS2 | |
| SCHEMBL7090581 | 0.73 | PTGS2 (0.53) | PTGS2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | PTGS2 122/4885MAOB 2849/4885NR1H2 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.